Soligenix
29 Emmons Drive
Suite C-10
Princeton
New Jersey
08540
United States
Tel: 609-538-8200
Fax: 609-452-6467
Website: http://www.soligenix.com/
414 articles about Soligenix
-
Soligenix Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development of OrbeShield In GI ARS
8/27/2015
-
Soligenix Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development Of Heat Stable Ricin Vaccine
8/19/2015
-
Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results
8/12/2015
-
Soligenix Receives Orphan Drug Designation From The European Commission (EC) For SGX301 As A Treatment For Cutaneous T-Cell Lymphoma
8/4/2015
-
Soligenix Enters Into A $10 Million Equity Purchase Agreement
8/3/2015
-
Soligenix Announces Collaboration With The National Organization for Rare Disorders And The Cutaneous Lymphoma Foundation In Advancing Its Phase 3 Study Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma
6/23/2015
-
Soligenix Announces Publication Of Successful Application Of Its Heat Stabilization Technology To A Human Papillomavirus Vaccine
6/2/2015
-
Soligenix Announces Collaboration With The University Of Hawai'i At Manoa And Hawaii Biotech To Develop Heat Stable Ebola Vaccine
5/28/2015
-
Soligenix Announces First Quarter 2015 Highlights And Financial Results
5/14/2015
-
Soligenix Announces Development Agreement With Emergent BioSolutions
5/13/2015
-
Soligenix Announces Presentation And Poster At The 2015 Chemical And Biological Defense Science And Technology Conference In St. Louis, MO
5/4/2015
-
Soligenix Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease
4/14/2015
-
Soligenix's CEO Christopher Schaber Interviewed By The Life Sciences Report
4/10/2015
-
DSG, Inc. Partners With Soligenix To Battle Cutaneous T-Cell Lymphoma
4/7/2015
-
Soligenix Announces Recent Accomplishments And Year-End 2014 Financial Results
3/24/2015
-
Soligenix Announces Publication Of Successful Preclinical Efficacy And Immunogenicity Results For Ricin Toxin Vaccine
3/11/2015
-
Soligenix To Present At The 27th Annual ROTH Conference
3/5/2015
-
Soligenix Announces Positive Recommendation By Data Review Committee On Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
3/3/2015
-
Soligenix Release: Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC
2/13/2015
-
12635 E. Montview Blvd. Release: Preclinical Melioidosis Results Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC
2/11/2015